Anixa Biosciences, Inc. ANIX
2.71 USD +0.04 (+1.50%)
Regular-session close
2.71 0.00 0.00%
After hours · Nov 18, 4:00 PM ET
2.64 Day range 2.83
2.32 52-week range 5.46
- YTD
- -13.14%
- 1 year
- -33.90%
News
benzinga.com Anixa Biosciences Taps Curia To Provide Formulation Development Services For Anixa's Investigational Breast Cancer Vaccine In Preparation For Upcoming Phase 2 Clinical Trial Collaboration to support development of a stable, scalable formulation for clinical development and potential commercializationSAN JOSE, Calif., Nov. 18, 2026 /PRNewswire/ -- Anixa Biosciences, Inc.…
prnewswire.com Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical Trial Collaboration to support development of a stable, scalable formulation for clinical development and potential commercialization SAN JOSE, Calif., Nov. 18, 2026 /PRNewswire/ -- Anixa Biosciences, Inc.…
prnewswire.com Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026 Dr. Robert Wenham, principal investigator of Anixa's Phase 1 clinical trial at Moffitt Cancer Center, to present on December 14 in London SAN JOSE, Calif., Nov. 4, 2026 /PRNewswire/ -- Anixa…
defenseworld.net Anixa Biosciences (NASDAQ:ANIX) Share Price Breaks Below 200-Day Moving Average – Time to Sell? Anixa Biosciences Inc (NASDAQ: ANIX - Get Free Report) shares crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $2.97 and traded as low as…benzinga.com Anixa Biosciences Completes Dosing Of Fifth Group In Its Phase 1 Clinical Study Of FSHR-Targeted CAR-T Therapy To Treat Ovarian Cancer Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has completed dosing of the fifth
prnewswire.com Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial First patient in fifth cohort exhibiting stable disease 90 days after treatment Multiple patients surviving more than one year, including one beyond two years, with no dose-limiting toxicities…
prnewswire.com Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference Dr. Jose Conejo-Garcia will speak on immunotherapy for ovarian cancer at the November 2–3 conference SAN JOSE, Calif., Oct. 13, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company")…
prnewswire.com Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial First patient in current dose cohort exhibited no progression of her cancer three months aftertreatment Multiple patients have survived more than one year, including one beyond two years No…
prnewswire.com Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial Multiple Patients Surviving More Than One Year, Including One Beyond Two Years, With No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 Will Receive 1×10⁷ CAR-Positive Cells/kg…
defenseworld.net Anixa Biosciences (NASDAQ:ANIX) Stock: Insider Arnold Baskies Purchases 5,000 Shares Anixa Biosciences Inc (NASDAQ: ANIX - Get Free Report) Director Arnold Baskies purchased 5,000 shares of the firm's stock in a transaction on Thursday, September 24th. The shares were acquired at an…
defenseworld.net Insider Buying: Anixa Biosciences (NASDAQ:ANIX) CEO Buys $19,460.00 in Stock Anixa Biosciences Inc (NASDAQ: ANIX - Get Free Report) CEO Amit Kumar acquired 7,000 shares of Anixa Biosciences stock in a transaction that occurred on Thursday, September 24th. The shares were…
prnewswire.com Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040 Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in Australia through 2040, expanding the Company's growing global IP estate Continues expansion of global…
prnewswire.com Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board SAN JOSE, Calif., Sept. 16, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today…
prnewswire.com Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV SAN JOSE, Calif., Sept. 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today…
prnewswire.com Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026 Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research institutions — Cleveland Clinic and Moffitt Cancer Center SAN JOSE, Calif., Sept. 3, 2026…
prnewswire.com Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined immune responses in 74% of participants—Phase 2 preparations ongoing Ovarian cancer CAR-T therapy,…
prnewswire.com Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with lymphodepletion—four patients surpass one year of survival, longest at approximately 28 months…
zacks.com Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here's What You Should Know Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
zacks.com New Strong Buy Stocks for July 22nd HTLD, YEXT, ANIX, WVE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 2026.
prnewswire.com Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology Notice of Acceptance marks first Australian patent covering Anixa's breast cancer vaccine platform Continues expansion of global intellectual property coverage in markets with increasing breast…
prnewswire.com Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 will receive 1×10⁷ CAR-positive cells/kg…
prnewswire.com Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040 Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in South Korea through 2040, expanding the Company's growing global IP estate Expands global intellectual…
